EHA 2025: Hematology Advances & Global Reach
- Milan,Italy,will host the 2025 European Hematology Association (EHA) Congress from June 12-15,gathering clinicians,researchers,and innovators to discuss the latest trends in hematology.
- Responding to attendee feedback, organizers have strategically dispersed the sessions while maintaining popular formats such as posters, panels, symposia, and workshops.
- The congress will include thematic debates on controversial topics, such as the value of prophylactic platelet transfusions and optimal care standards for diffuse large B-cell lymphoma (DLBCL).
the 2025 European Hematology Association (EHA) Congress in Milan is primed to spotlight crucial advancements, with over 130 sessions examining the latest breakthroughs in hematology research. From gene therapy options for sickle cell disease and thalassemia to the impact of emotional burdens in hematology, the event offers a complete overview.expect robust debates on platelet transfusions and cutting-edge DLBCL treatments. News Directory 3 recognizes this crucial congregation of clinicians and researchers. With plenary sessions unveiling phase 3 results and the exploration of minimal residual disease (MRD), the congress promises compelling insights impacting practice across the lifespan. Discover what’s next for hematology.
Hematology Innovation Takes Center Stage at EHA Congress 2025 in Milan
Updated June 06,2025
Milan,Italy,will host the 2025 European Hematology Association (EHA) Congress from June 12-15,gathering clinicians,researchers,and innovators to discuss the latest trends in hematology. the congress will feature over 130 sessions and 4000 abstracts, offering a complete overview of advancements in the field of hematology.
Responding to attendee feedback, organizers have strategically dispersed the sessions while maintaining popular formats such as posters, panels, symposia, and workshops. The YoungEHA sessions will address topics ranging from hematological issues in space to the emotional challenges faced by hematology practitioners.
The congress will include thematic debates on controversial topics, such as the value of prophylactic platelet transfusions and optimal care standards for diffuse large B-cell lymphoma (DLBCL). Building on last year’s discussions about gene therapy access for hemophilia,this year’s debates will focus on gene therapy versus transplant options for sickle cell disease and thalassemia.
Joint sessions with organizations like the European Society for Blood and Marrow Transplantation and the American Society of Hematology will also be featured. A joint symposium between EHA and the European Medicines Agency will explore the use of minimal residual disease (MRD) in clinical and regulatory decisions.
“The multistakeholder discussion will cover the importance of understanding MRD from the patient’s viewpoint and highlight the contrast between scientific enthusiasm and regulatory strictness,” EHA organizers said. “Specific cases will be used to highlight the differences in perspectives.”
Plenary and late-breaking abstract sessions are expected to draw large audiences eager to learn about the latest data. The plenary session will present phase 3 results on treatments for DLBCL, essential thrombocythemia, and graft-vs-host disease, along with early-stage findings on multiple myeloma and leukemias. Late-breaking data will include drug regimens and results from a novel frailty assessment.
A key theme throughout the congress is the continuum of hematology practice across the lifespan. Sessions will cover newborn screening for sickle cell disease, adolescent and young adult treatment considerations, and management of multiple myeloma and lymphoma in older patients. Poster presentations will showcase drug efficacy in pediatric populations and treatment patterns in older adults.
What’s next
The EHA Congress in Milan aims to equip attendees with the latest knowledge and practices in hematology, preparing them for advancements in clinical and laboratory settings.